Cite Filings / LXEO / 0000950170-25-019457
Feed Companies Filings Check
Sign in
SCHEDULE 13G

Statement of Beneficial Ownership

Lexeo Therapeutics, Inc. · Filed 2025-02-13 · Acc 0000950170-25-019457

Documents 1

  • SCHEDULE 13G Statement of Beneficial Ownership , xslSCHEDULE_13G_X01/primary_doc.xml

Around this filing

  • 2025-04-28 SCHEDULE 13G Statement of Beneficial Ownership
  • 2025-02-14 SCHEDULE 13G/A Statement of Beneficial Ownership
  • 2025-02-14 SCHEDULE 13G/A Statement of Beneficial Ownership
  • 2025-02-14 SCHEDULE 13G/A Statement of Beneficial Ownership
  • 2025-02-13 SCHEDULE 13G Statement of Beneficial Ownership
  • 2025-02-12 SCHEDULE 13G/A Statement of Beneficial Ownership
  • 2025-02-04 SCHEDULE 13G Statement of Beneficial Ownership

Link to a passage

At least 12 characters, not counting spaces, so the link points to one passage.

External

  • SEC EDGAR (opens in new tab)

Stakes reported in this filing

Stake history · largest stake in each 13D and 13G

  1. 2026-11-16 SCHEDULE 13G/A · JANUS HENDERSON GROUP Ltd. 7.2%
  2. 2026-11-16 SCHEDULE 13G/A · BALYASNY ASSET MANAGEMENT L.P. 9.99%
  3. 2026-11-16 SCHEDULE 13G/A · Paradigm BioCapital Advisors LP 0.0%
  4. 2026-11-16 SCHEDULE 13G/A · OrbiMed Advisors LLC 3.9%
  5. 2026-11-16 SCHEDULE 13G/A · Vestal Point Capital, LP 6.3%
  6. 2026-11-13 SCHEDULE 13G/A · Affinity Asset Advisors, LLC 9.8%
Loading xslSCHEDULE_13G_X01/primary_doc.xml…

Connection lost

Reconnecting…

Cite Filings isn't responding

Reconnecting…